Orgenesis Inc.
ORGS evidence brief
What we can confirm
- BioSniper Score:
- 2.4 / 10
- Market Cap:
- $3.4M
- Lead Asset:
- mdvac (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ORGS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ORGS
Orgenesis Inc. (ORGS) is a biotechnology company developing personalized cell therapies and a point-of-care (POCare) network, with a preclinical cancer immunotherapy candidate and a history of asset sales to fund operations.
Key risk: Cash runway risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$3.4M
Cash Runway
—
Lead Asset
mdvac (Preclinical)
Next Catalyst
—
Financial data as of Dec 31, 2024.
Tracking 1 pipeline candidate for Orgenesis Inc..
Orgenesis Inc. (ORGS) is a biotechnology company developing personalized cell therapies and a point-of-care (POCare) network, with a preclinical cancer immunotherapy candidate and a history of asset sales to fund operations.
- Cash & equivalents of $0.1M as of 2024-12-31 [sec].
- Shareholders' equity of -$37.5M as of 2024-12-31 [sec].
- Pipeline candidate mdvac is a preclinical dual vaccine cell-based cancer immunotherapy for solid tumors, licensed from Columbia University [pipeline].
- In March 2026, Orgenesis sold the global IP and development assets for ranpirnase to Okogen Inc. [news].
- As of September 2025, Orgenesis repaid $6.3 million of outstanding debt [sec_mda].
What works
- Orgenesis has a decade of internal knowhow in the cell therapy field and a POCare Network that partners with hospitals and research institutes to lower development costs through joint grants and regional partnerships [sec_mda].
- The company's out-licensing model allows it to minimize pre-clinical development costs and receive additional funding from grants and payments by regional partners [sec_mda].
What to weigh
- Cash & equivalents are only $0.1M as of 2024-12-31, and shareholders' equity is deeply negative at -$37.5M [sec].
- There is no assurance that the business will generate sustainable positive cash flows to fund operations and satisfy debt obligations [sec_mda].
- The company's only disclosed pipeline candidate (mdvac) is in preclinical phase, with no clinical data yet, and faces a competitive landscape of over 370 competitors in solid tumors [pipeline].
From the filings
Quoted directly from source documents.
Orgenesis sold ranpirnase assets in March 2026
“Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc.”
News · March 26, 2026
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash & equivalents of only $0.1M as of 2024-12-31 [sec].
- Negative equity — Shareholders' equity of -$37.5M as of 2024-12-31 [sec].
- No sustainable cash flows — No assurance of sustainable positive cash flows to fund business and debt [sec_mda].
- Preclinical pipeline only — Only disclosed candidate is preclinical, with no clinical data [pipeline].
What to watch
- Ability to secure additional financing or partnerships given minimal cash and negative equity [sec_mda].
- Progress of the preclinical mdvac candidate toward IND and clinical trials [pipeline].
- Impact of the ranpirnase asset sale on revenue and pipeline [news].
- Any further asset sales or debt repayments that affect financial runway [sec_mda].
Sources: Competitor trials · News · Pipeline · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run Orgenesis Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Orgenesis Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
N/A
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 1.3%
- Days to cover
- 2.4
- Shares short
- 56,251
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ORGS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Orgenesis Inc.?
Orgenesis Inc. (ORGS) is a biotechnology company developing personalized cell therapies and a point-of-care (POCare) network, with a preclinical cancer immunotherapy candidate and a history of asset sales to fund operations.
What is Orgenesis Inc.'s lead drug candidate?
Orgenesis Inc.'s most advanced tracked candidate is mdvac (Preclinical) for Solid Tumors.
Who is the CEO of Orgenesis Inc.?
Ms. Vered Caplan M.Sc. is the chief executive officer of Orgenesis Inc. (ORGS).
Where is Orgenesis Inc. headquartered?
Orgenesis Inc. (ORGS) is headquartered in Germantown, MD, United States.
What therapeutic areas does Orgenesis Inc. focus on?
Orgenesis Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.